Ginkgo Bioworks Holdings (DNA) Net Cash Flow (2020 - 2026)

Ginkgo Bioworks Holdings (DNA) has reported Net Cash Flow for 7 consecutive years, with -$16.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow rose 83.98% year-over-year to -$16.7 million; the trailing twelve-month figure through Jun 2026 stood at -$79.2 million (up 84.9% YoY), and the FY2025 full-year result was -$393.6 million, down 2.61% from the prior year.
• Net Cash Flow advanced to -$16.7 million in Q2 2026 per DNA's latest filing, from -$23.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $55.6 million in Q4 2025 and bottomed at -$250.4 million in Q1 2025.
• Historically, Net Cash Flow has averaged -$78.9 million across 5 years, with a median of -$90.3 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Net Cash Flow plunged 557.67% in 2023, then jumped 199.71% in 2025.
• Over 5 years, Net Cash Flow stood at $23.0 million in 2022, then slumped by 557.67% to -$105.1 million in 2023, then surged by 47.0% to -$55.7 million in 2024, then surged by 199.71% to $55.6 million in 2025, then slumped by 130.05% to -$16.7 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$16.7 million, -$23.6 million, and $55.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.